Clinical Use of Tecovirimat (Tpoxx) for Treatment of Monkeypox Under an Investigational New Drug Protocol - United States, May-August 2022.
Journal
MMWR. Morbidity and mortality weekly report
ISSN: 1545-861X
Titre abrégé: MMWR Morb Mortal Wkly Rep
Pays: United States
ID NLM: 7802429
Informations de publication
Date de publication:
16 Sep 2022
16 Sep 2022
Historique:
entrez:
15
9
2022
pubmed:
16
9
2022
medline:
20
9
2022
Statut:
epublish
Résumé
Currently, no Food and Drug Administration (FDA)-approved treatments for human monkeypox are available. Tecovirimat (Tpoxx), however, is an antiviral drug that has demonstrated efficacy in animal studies and is FDA-approved for treating smallpox. Use of tecovirimat for treatment of monkeypox in the United States is permitted only through an FDA-regulated Expanded Access Investigational New Drug (EA-IND) mechanism. CDC holds a nonresearch EA-IND protocol that facilitates access to and use of tecovirimat for treatment of monkeypox.
Identifiants
pubmed: 36107794
doi: 10.15585/mmwr.mm7137e1
pmc: PMC9484807
doi:
Substances chimiques
Antiviral Agents
0
Drugs, Investigational
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1190-1195Investigateurs
Sarah Ahmadi
(S)
Rachel Avery
(R)
Kathryn Bean
(K)
Leah Beavers
(L)
Kim Belanger Giguere
(K)
Joi Brownlee
(J)
Catherine Campbell
(C)
Maggie Cheng
(M)
Rachel Clinton
(R)
Taylor Coleman
(T)
Monique S Davis
(MS)
Marie Dubreus
(M)
Meryl Henry
(M)
Sujeith B Lozoya
(SB)
Jahnae Morgan
(J)
Kalimah Muhammad
(K)
Corinne M Parker
(CM)
Nigel Peters
(N)
Ellery Rybak
(E)
Andrew Schwenk
(A)
Jessica van Loben Sels
(J)
Max Veillard
(M)
Déclaration de conflit d'intérêts
All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Riad Elmor reports contract support (DCIPHER Program Management and Data Analytic Services) from Booz Allen Hamilton. No other potential conflicts of interest were disclosed.
Références
N Engl J Med. 2018 Jul 5;379(1):44-53
pubmed: 29972742
JAMA. 2022 Aug 22;:
pubmed: 35994281
MMWR Morb Mortal Wkly Rep. 2022 Aug 12;71(32):1018-1022
pubmed: 35951487
Clin Infect Dis. 2022 Jul 29;:
pubmed: 35904001
Lancet Infect Dis. 2022 Sep;22(9):1321-1328
pubmed: 35785793
Lancet Infect Dis. 2022 Aug;22(8):1153-1162
pubmed: 35623380
J Virol. 2011 Sep;85(17):9176-87
pubmed: 21697474
Antiviral Res. 2019 Aug;168:168-174
pubmed: 31181284
Clin Infect Dis. 2020 Nov 5;71(8):e210-e214
pubmed: 32052029
MMWR Morb Mortal Wkly Rep. 2022 Sep 09;71(36):1155-1158
pubmed: 36074752